Astria Therapeutics (NASDAQ:ATXS) Earns “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note published on Tuesday, Benzinga reports. They currently have a $22.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for Astria Therapeutics’ Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.68) EPS, Q2 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at ($2.22) EPS and FY2028 earnings at ($1.30) EPS.

A number of other equities analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They set a buy rating and a $35.00 price objective for the company. Finally, Oppenheimer lowered their target price on shares of Astria Therapeutics from $29.00 to $25.00 and set an outperform rating on the stock in a report on Tuesday, May 21st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of Buy and a consensus target price of $25.20.

Astria Therapeutics Price Performance

ATXS opened at $11.07 on Tuesday. The company has a market capitalization of $607.89 million, a P/E ratio of -4.77 and a beta of 0.73. The firm’s fifty day moving average price is $10.12 and its two-hundred day moving average price is $11.37. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, equities research analysts expect that Astria Therapeutics will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ATXS. Vivo Capital LLC grew its holdings in Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after acquiring an additional 801,528 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Astria Therapeutics during the fourth quarter valued at approximately $1,469,000. Tidal Investments LLC acquired a new stake in shares of Astria Therapeutics in the first quarter valued at approximately $1,664,000. Finally, Perceptive Advisors LLC raised its position in Astria Therapeutics by 82.9% in the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares during the last quarter. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.